Paper6966652
In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.
Yron I and 3 others. J Immunol, 1980. Cited by 262 papers, by iCite.
Cite this record
ConductScience Library. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. Papers, record 6966652. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6966652
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cell Transformation, Neoplastic | Major topic |
| Sarcoma, Experimental | Major topic |
| T-Lymphocytes | Major topic |
| Animals | |
| Cell Division | |
| Cell Separation | |
| Cells, Cultured | |
| Cytotoxicity, Immunologic | |
| Female | |
| Growth Substances | |
| Histiocytes | |
| Lymphocytes | |
| Mice | |
| Mice, Inbred C57BL |
Source PubMed
Cited by57
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 262 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42272961 | Adoptive T-cell therapies in the clinic. | Bioeng Transl Med | 2026 | https://conductscience.org/library/papers/42272961 | PubMed |
| 42099873 | Advances in cell therapy for solid tumours: European perspective and future directions. | Lancet Reg Health Eur | 2026 | https://conductscience.org/library/papers/42099873 | PubMed |
| 41058692 | Recent advances in adoptive cell therapy for cancer immunotherapy. | Front Immunol | 2025 | https://conductscience.org/library/papers/41058692 | PubMed |
| 40765841 | Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges. | BMJ Oncol | 2025 | https://conductscience.org/library/papers/40765841 | PubMed |
| 39129675 | Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study. | Future Oncol | 2024 | https://conductscience.org/library/papers/39129675 | PubMed |
| 39012213 | Lifileucel: FDA-approved T-cell therapy for melanoma. | Oncologist | 2024 | https://conductscience.org/library/papers/39012213 | PubMed |
| 38666543 | Developing innovative strategies of tumor‑infiltrating lymphocyte therapy for tumor treatment. | Oncol Rep | 2024 | https://conductscience.org/library/papers/38666543 | PubMed |
| 38503296 | FDA approval of the first cellular therapy for a solid (non-hematologic) cancer. | Mol Ther | 2024 | https://conductscience.org/library/papers/38503296 | PubMed |
| 37345057 | Recent Advances in Molecular Mechanisms of Cancer Immunotherapy. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37345057 | PubMed |
| 34140957 | Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer. | Front Immunol | 2021 | https://conductscience.org/library/papers/34140957 | PubMed |
| 34134616 | Immersion in the search for effective cancer immunotherapies. | Mol Med | 2021 | https://conductscience.org/library/papers/34134616 | PubMed |
| 33335718 | Cancer T-cell therapy: building the foundation for a cure. | F1000Res | 2020 | https://conductscience.org/library/papers/33335718 | PubMed |
| 32975147 | Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia. | Expert Rev Clin Immunol | 2020 | https://conductscience.org/library/papers/32975147 | PubMed |
| 32879472 | Human immunology and immunotherapy: main achievements and challenges. | Cell Mol Immunol | 2021 | https://conductscience.org/library/papers/32879472 | PubMed |
| 32612154 | The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. | Cell Mol Immunol | 2020 | https://conductscience.org/library/papers/32612154 | PubMed |
| 29700396 | A history of exploring cancer in context. | Nat Rev Cancer | 2018 | https://conductscience.org/library/papers/29700396 | PubMed |
| 29456568 | Harnessing the immune system in the battle against breast cancer. | Drugs Context | 2018 | https://conductscience.org/library/papers/29456568 | PubMed |
| 29443657 | IL-2 and Beyond in Cancer Immunotherapy. | J Interferon Cytokine Res | 2018 | https://conductscience.org/library/papers/29443657 | PubMed |
| 28729866 | Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy. | Front Immunol | 2017 | https://conductscience.org/library/papers/28729866 | PubMed |
| 26037048 | The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer. | Curr Top Microbiol Immunol | 2016 | https://conductscience.org/library/papers/26037048 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6966652
GET https://conductscience.org/api/papers/v1/6966652/cited_by?page=2